HC Wainwright Reaffirms Buy Rating for Esperion Therapeutics (NASDAQ:ESPR)

HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a report released on Thursday,Benzinga reports. The brokerage currently has a $16.00 price objective on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a research report on Friday, December 13th. The Goldman Sachs Group assumed coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price objective on the stock. Cantor Fitzgerald assumed coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price objective on the stock. Finally, JMP Securities reissued a “market outperform” rating and set a $4.00 price target (down from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Esperion Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $6.75.

Esperion Therapeutics Trading Up 4.3 %

ESPR stock opened at $1.69 on Thursday. The stock has a market capitalization of $334.36 million, a PE ratio of -2.64 and a beta of 1.04. Esperion Therapeutics has a 12-month low of $1.47 and a 12-month high of $3.94. The stock’s 50 day simple moving average is $1.84 and its 200 day simple moving average is $2.07.

Institutional Investors Weigh In On Esperion Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Cibc World Markets Corp purchased a new stake in shares of Esperion Therapeutics in the 4th quarter worth $39,000. SJS Investment Consulting Inc. purchased a new stake in shares of Esperion Therapeutics in the 4th quarter worth $55,000. Crestline Management LP purchased a new stake in shares of Esperion Therapeutics in the 4th quarter worth $63,000. Foundations Investment Advisors LLC increased its stake in shares of Esperion Therapeutics by 48.6% in the 4th quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 9,872 shares in the last quarter. Finally, J.W. Cole Advisors Inc. purchased a new stake in shares of Esperion Therapeutics in the 4th quarter worth $66,000. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.